Asthma, in general, is a respiratory disorder that affects millions of Americans each year.
Reasonably priced, effective treatments have been developed by several pharmacological
companies designed to treat this condition by various mechanisms. Levalbuterol has recently
been developed and marketed as a direct beta2 agonist with improved efficacy in symptom relief
as well as an improved side effect profile. A direct superiority study comparing side effect
profiles of both racemic albuterol and levalbuterol concluded that no significant improvement
was noticed with respect to side effect profiles between the two medications.
The information provided in this handout does not necessarily reflect the views of the University of Minnesota Medical School physicians and faculty. These materials are provided for informational purposes only and are in no way intended to take the place of the advice and recommendations of your personal health care provider. You use the information provided in these handouts at your own risk.
Does Levalbuterol (Xopenex®) Live Up to the Hype?.
Retrieved from the University of Minnesota Digital Conservancy,
Content distributed via the University of Minnesota's Digital Conservancy may be subject to additional license and use restrictions applied by the depositor.